Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GPCR Stock 12 Month Forecast
Average Price Target
$74.00
▲(114.06% Upside)
| Highest Price Target$100.00 | Average Price Target$74.00 | Lowest Price Target$50.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
$50
Buy
44.63%
Upside
Reiterated
12/02/25
H.C. Wainwright
$60
Buy
73.56%
Upside
Reiterated
11/26/25
Jefferies
$79
Buy
128.52%
Upside
Reiterated
11/25/25
LifeSci Capital
$72
Buy
108.27%
Upside
Reiterated
11/24/25
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin AgonistsAt obesity week 2025, Lilly’s (NYSE: LLY) eloralinde (Q W, injectable amylin agonist) impressed the field and demonstrated compelling semaglude-lik e efficacy coupled with prisne GI-t olerability in the monotherapy seng in a Phase 2 study (n=263). As a result, we thought it suitable to conduct a 20-slide “cold plunge” on amylin, which is more to-the-point than a tradional “ deep dive” (and hopefully more therapeuc), t o evaluate how this class might fit into the highly compev e obesity arena. Within, we discuss the amylin mechanism relav e to that of glucagon-like pepde-1 (GLP -1), analyze the clinical-stage compev e landscape, and evaluate the potenal f or Structure’s (NASDAQ: GPCR) small molecule amylin agonists (ACCG- 2671 and ACCG-3535) as they approach the clinic.
BMO Capital
$100
Buy
189.27%
Upside
Reiterated
11/20/25
Cantor Fitzgerald
$65
Buy
88.02%
Upside
Reiterated
11/13/25
William Blair
―
Buy
―
Reiterated
11/04/25
Citi
$60
Buy
73.56%
Upside
Reiterated
11/03/25
Piper Sandler
$93
Buy
169.02%
Upside
Reiterated
10/28/25
Citizens JMP
$87
Buy
151.66%
Upside
Reiterated
09/17/25
J.P. Morgan
―
Buy
―
Reiterated
09/04/25
Leerink Partners
$60→$44
Buy
27.28%
Upside
Reiterated
08/07/25
Guggenheim
$92→$90
Buy
160.34%
Upside
Reiterated
08/06/25
Clear Street
$61
Buy
76.45%
Upside
Initiated
07/30/25
Morgan Stanley
$118→$120
Buy
247.12%
Upside
Reiterated
05/12/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
$50
Buy
44.63%
Upside
Reiterated
12/02/25
H.C. Wainwright
$60
Buy
73.56%
Upside
Reiterated
11/26/25
Jefferies
$79
Buy
128.52%
Upside
Reiterated
11/25/25
LifeSci Capital
$72
Buy
108.27%
Upside
Reiterated
11/24/25
Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin AgonistsAt obesity week 2025, Lilly’s (NYSE: LLY) eloralinde (Q W, injectable amylin agonist) impressed the field and demonstrated compelling semaglude-lik e efficacy coupled with prisne GI-t olerability in the monotherapy seng in a Phase 2 study (n=263). As a result, we thought it suitable to conduct a 20-slide “cold plunge” on amylin, which is more to-the-point than a tradional “ deep dive” (and hopefully more therapeuc), t o evaluate how this class might fit into the highly compev e obesity arena. Within, we discuss the amylin mechanism relav e to that of glucagon-like pepde-1 (GLP -1), analyze the clinical-stage compev e landscape, and evaluate the potenal f or Structure’s (NASDAQ: GPCR) small molecule amylin agonists (ACCG- 2671 and ACCG-3535) as they approach the clinic.
BMO Capital
$100
Buy
189.27%
Upside
Reiterated
11/20/25
Cantor Fitzgerald
$65
Buy
88.02%
Upside
Reiterated
11/13/25
William Blair
―
Buy
―
Reiterated
11/04/25
Citi
$60
Buy
73.56%
Upside
Reiterated
11/03/25
Piper Sandler
$93
Buy
169.02%
Upside
Reiterated
10/28/25
Citizens JMP
$87
Buy
151.66%
Upside
Reiterated
09/17/25
J.P. Morgan
―
Buy
―
Reiterated
09/04/25
Leerink Partners
$60→$44
Buy
27.28%
Upside
Reiterated
08/07/25
Guggenheim
$92→$90
Buy
160.34%
Upside
Reiterated
08/06/25
Clear Street
$61
Buy
76.45%
Upside
Initiated
07/30/25
Morgan Stanley
$118→$120
Buy
247.12%
Upside
Reiterated
05/12/25
Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR
1 Month
xxx
Success Rate
11/17 ratings generated profit
Average Return
+8.72%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +8.72% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+14.68%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +14.68% per trade.
1 Year
Success Rate
9/9 ratings generated profit
Average Return
+48.09%
reiterated a buy rating 7 days ago
Copying Ananda Ghosh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.09% per trade.
2 Years
xxx
Success Rate
9/9 ratings generated profit
Average Return
+48.09%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +48.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GPCR Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
14
13
15
17
20
Buy
1
1
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
14
17
19
22
Each month's total comprises the sum of three months' worth of ratings.
GPCR Financial Forecast
GPCR Stock Forecast FAQ
What is GPCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 74.00.
What is GPCR’s upside potential, based on the analysts’ average price target?
Structure Therapeutics, Inc. Sponsored ADR has 114.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GPCR a Buy, Sell or Hold?
Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Structure Therapeutics, Inc. Sponsored ADR’s price target?
The average price target for Structure Therapeutics, Inc. Sponsored ADR is 74.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $50.00. The average price target represents 114.06% Increase from the current price of $34.57.
The highest analyst price target is $100.00 ,the lowest forecast is $50.00. The average price target represents 114.06% Increase from the current price of $34.57.
What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?
Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of GPCR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.